000 03664nam a22003495i 4500
001 75923
003 ES-MaUEC
005 20230202101812.0
007 cr nn 008mamaa
008 121116s2013 xxu| s |||| 0|eng d
020 _a9781461458470
040 _aES-MaUEC
050 4 _aRC268.4
_b.C35 2013 EB
245 0 0 _aCell Death Signaling in Cancer Biology and Treatment
_cedited by Daniel E. Johnson
260 _aNew York
_bSpringer International Publishing
_c2013
300 _a1 recurso en línea (XVI, 405 p.) 40 il., 31 il. col.
336 _aTexto (visual)
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
490 1 _aCell Death in Biology and Diseases
520 _aDefects in cell death pathways promote tumor development and progression, with potentially devastating consequences for cancer patients.Â{u01F2}eater understanding of the defects occurring in cancer cells, and the unique characteristics of tumors which can make them vulnerable to cell death stimuli, offers tremendous opportunities for developing novel and effective anti-cancer therapies.Â{u026E} Cell Death in Cancer Biology and Treatment leading experts in the field provide a wealth of up-to-date knowledge regarding the molecular mechanisms and cell biological processes that control cell death.šch chapter also highlights recent advances in the translation of basic research findings into clinical trials.Â{u00A5}ginning and established investigators alike will benefit from the thorough presentations of the most promising avenues for future development of cell death-based, anti-cancer strategies and agents. TheÂ{u6BEC}ume begins with a detailed description of many of the cell death defects that have been identified in human tumor specimens.The unique bioenergetics of cancer cells, and the influence of the tumor microenvironment, autophagy, and cellular microRNAs on cancer cell death are then discussed, along with current progress in targeting these distinctive features and processes.Âdditional chapters describe recent advances, and the therapeutic benefits of targeting DNA repair pathways, protein chaperones, sphingolipid signaling, Bcl-2 family members, IAPs, death receptor signaling, the proteasome, and survival signaling emanating from the PI3K/AKT and RAS/RAF/MEK/ERK pathways.Â{u01A9}nally, recent discoveries are presented regarding interactions between the immune system and dying cancer cells and the potential for optimizing these interactions to maximize anti-cancer activities.Â{u026E} summary, Cell Death in Cancer Biology and Treatment will be a valuable resource for scientists interested in cutting-edge understanding of aberrant cell death in cancer cells, and the multitude of innovative molecular targeting approaches that are actively being pursued to achieve selective activation of cell death in human malignancies.
942 _2lcc
_cLE
988 _aEBOOK, EBSPRINGERrevisado
650 7 _aCáncer
_xAspectos genéticos
_9273952
_0comprobar BNE19990911214
_2embne
700 1 _aJohnson, Daniel E.
_eeditor literario
_984650
_0Local
830 0 _aCell Death in Biology and Diseases
_9133174
_0Local
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-5847-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901 _ai9781461458470
907 _a.b1281541x
_b10-10-17
_c01-10-14
998 _am
_a_alco
_a_vill
_b10-03-17
_cm
_dz
_ef
_feng
_gxxu
_h0
945 _aRC268.4 .C35 2013 EB
_g1
_ieBOOK
_j0
_lmae
_o-
_pEUR0.00
_q-
_r-
_sb
_t15
_u0
_v0
_w0
_x0
_y.i1154479x
_z06-04-17
999 _c75923
_d75923
_x1